Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study. 1992

K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
Section of Medical Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.

Based on recent preclinical data suggesting synergism between 5-fluorouracil (5-FU) and interferon alpha (IFN-alpha) and clinical activity of the combination therapy in colon cancer, 14 patients with advanced gastric cancer were treated with combination therapy of 5-FU and recombinant interferon alpha-2b (rIFN alpha-2b) (Intron A, Schering, Kenilworth, NJ, U.S.A.). The maximum tolerated dose was 5-FU 750 mg/m2/day given as a continuous infusion daily for 5 days followed by weekly bolus injection of the same initial daily dose, plus rIFN alpha-2b 5 X 10(6) U given subcutaneously 3 times weekly starting day 1 of 5-FU infusion. The dose-limiting toxicities were fatigue/weakness, diarrhea, and neurologic toxicities such as somnolence and confusion. The other common side effects were nausea, fever, leukocytopenia, thrombocytopenia, and the darkening of the skin. Of 13 evaluable patients, 4 had a partial response (duration 6, 14, 24, and 28 weeks). These data suggest that combination therapy of 5-FU plus rIFN alpha-2b is tolerable and has manageable side effects in patients with advanced gastric cancer. Further Phase II study will be needed to define the antitumor activity of this combination.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
January 1995, Cancer chemotherapy and pharmacology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
February 1995, Annals of oncology : official journal of the European Society for Medical Oncology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
February 1996, The Journal of urology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
January 1992, European journal of cancer (Oxford, England : 1990),
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
April 1992, Seminars in oncology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
April 1992, Seminars in oncology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
January 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
October 1993, Cancer,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
June 1994, American journal of clinical oncology,
K H Lee, and J S Lee, and C Suh, and Y S Lee, and Y I Min, and S H Ahn, and K C Park, and S K Kim, and S H Kim
August 1993, Cancer research,
Copied contents to your clipboard!